We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Lawsuits seeking to force hospitals to administer ivermectin to COVID-19 patients show no signs of slowing in recent weeks — despite repeated warnings by regulators against such use. Read More
Molnupiravir, the controversial COVID-19 oral antiviral made by Merck and subsidiary Ridgeback Therapeutics, will have its day in committee, the FDA has announced. Read More
A day after its unanimous vote in favor of Moderna’s COVID-19 booster shot, a panel of vaccine experts that advises the FDA also voted unanimously to grant Johnson & Johnson’s (J&J) COVID-19 booster shot Emergency Use Authorization (EUA). Read More
Researchers from the National Institutes of Health (NIH) have found that a “mix and match” approach using different COVID-19 booster vaccines is safe and effective. Read More
Just two days in advance of an independent advisory committee meeting to discuss whether or not the FDA should grant Emergency Use Authorization (EUA) to Moderna’s COVID-19 booster shot, the FDA has released documents saying Moderna hadn’t met all of the agency’s criteria to support use of a booster. Read More
Merck and Ridgeback Biotherapeutics have become the first companies to file an application seeking Emergency Use Authorization (EUA) for an oral antiviral that treats COVID-19 — which could transform treatment of infections with the deadly virus. Read More
Pfizer and BioNTech have filed for FDA authorization of their COVID-19 vaccine for inoculating children aged five to 11 years and the agency’s vaccine advisory panel will take up the matter at its previously scheduled meeting on Oct. 26 to consider the request. Read More